Home › Testicular Cancer › NCT05611307
Late Subclinical Cardiovascular Disease in Testicular Cancer Survivors
RecruitingObservational study
Detection of Late Subclinical Cardiovascular Disease in Testicular Cancer Survivors Exposed to Cisplatin-based Chemotherapy and Bone Marrow Transplant
Who can join
Ages 18 to 99 · Men
Full eligibility criteria
Inclusion Criteria * Patients \>18 years of age * Patients will be recruited only if cancer-free at clinical evaluation time. * For the cases a confirmed TC diagnosis who received one or more cycles of CBCT-based chemotherapies (CBCT group, Arm 2) * For the cases with a confirmed TC diagnosis who received one or more cycles of CBCT-based chemotherapies and underwent BMT for relapsed refractory disease (CBCT \& BMT group, Arm 3). * For the comparison cohort, biopsy-proven TC patients who had surgery for or surveillance of their testicular cancer and never received CBCTCBCT or BMT (surgical/surveillance, Arm 1) Exclusion Criteria * Prior known myocardial infarction (MI), atherosclerotic cardiovascular disease (ASCVD) * Significant renal disease (GFR\<40) * Allergy to iodinated contrast * Antecedent chemotherapy for another primary cancer.
About the study
Late subclinical cardiovascular disease in testicular cancer survivors exposed to cisplatin-based chemotherapy and bone marrow transplant
What is being tested
- Lipid profile (diagnostic test)
- Coronary artery assessment (diagnostic test)
- Hormone levels for hypogonadism (diagnostic test)
Sponsor: Indiana University · Participants: 150 · Started: Oct 11, 2022
Contact the study team
- Elizabeth Rowe · Phone: 317-278-1185
Official record on ClinicalTrials.gov — NCT05611307
Locations in the U.S.
| Indiana | Indiana University, Indianapolis |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.